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The negative regulatory element (NRE) of the hepatitis B virus (HBV) core promoter contains three subregions which act
synergistically to suppress core promoter activity. One of these subregions, NREg, is active in both HeLa cervical carcinoma
cells and Huh7 hepatoma cells and was found to be bound by a protein factor present in both cell types. Here we show
that the transcription factor RFX1 can bind to NREg and transactivate the core promoter through this site. Mutations
which abrogated the gene-suppressive activity of NREg prevented RFX1 from binding to NREg. In addition, RFX1 can bind
simultaneously, most likely as a heterodimer, with the transcription factor MIBP1 to NREg. In the absence of a cloned
MIBP1 gene for further studies, we hypothesize that RFX1 acts with MIBP1 to negatively regulate the core promoter activity
through the NREg site. The ability of RFX1 to transactivate the core promoter raises the possibility that RFX1 may play a
dual role in regulating HBV gene expression. q 1997 Academic Press
Hepatitis B virus (HBV) is a hepatotropic virus with a By performing deletion-mapping analysis, the NRE has
circular DNA genome of 3.2 kb. Despite its small size, been divided into three subregions termed NREa, NREb,
the HBV genome encodes four genes which lead to the and NREg (4). In HeLa cells, each of these subregions
production of at least seven viral gene products. The possesses a weak 2- to 3-fold suppressing activity, but
expression of HBV genes is regulated by four promoters together they generate a strong synergistic suppressing
and two enhancer elements (for a review, see 1). One of effect of 10- to 20-fold. In liver-derived Huh7 hepatoma
these promoters, termed the core promoter, regulates cells, only the NREg subregion is active; the NREa and
the transcription of HBV e antigen and core antigen NREb subregions are not (4, 6). The active NREg motif
mRNAs. The core mRNA also encodes the HBV DNA has been mapped to a 20-basepair region between nu-
polymerase and is the pregenomic RNA required for rep- cleotides 1605 and 1625 by DNase I footprinting, methyl-
lication of the HBV DNA genome. ation interference, and mutagenesis analyses. In a UV
The core promoter is preceded by an enhancer ele- cross-linking experiment, a ubiquitous protein factor ap-
ment termed ENII enhancer (Fig. 1). This enhancer, which proximately 130 kDa in size was found to bind to the
has also been termed the core upstream regulatory ele- NREg site (4).
ment, activates the core promoter in a position- and ori- As shown in Fig. 1, there is an extensive sequence
entation-dependent manner (2). An HNF4 binding site, homology between the NREg motif and the consensus
which positively regulates the core promoter activity, has RFX1 transcription factor binding site (7). RFX1 is approxi-
been identified in the ENII enhancer (3). In cotransfection mately 130 kDa in size and was initially isolated due to
experiments, HNF4 has been found to transactivate the its ability to bind to the X-box motif of HLA class II promot-
core promoter 10- to 20-fold in the HeLa cervical carci- ers (8). This protein factor, which was subsequently found
noma cell line. Interestingly, this transactivation of the to be identical to the methylation-dependent DNA-bind-
core promoter activity is suppressed by an upstream ing protein (MDBP) (9), can function as a transactivator
negative regulatory element (NRE) in an orientation-inde- of the HBV ENI enhancer (10). Due to the sequence ho-
pendent manner in HeLa cells (3–5). mology between the NREg motif and the RFX1-binding
site, and to the size similarity between the 130-kDa
NREg-binding factor and RFX1, we have examined1 These authors contributed equally to this work.
2 Current address: National Institutes of Health, NIAMS, Arthritis whether these two factors might be identical. We per-
Rheumatology Branch, Lymphocyte Cell Biology Section, Building 10, formed an electrophoretic mobility shift assay (EMSA)9N262, 9000 Rockville Pike, Bethesda, MD 20892.
using a double-stranded oligonucleotide containing the3 To whom correspondence and reprint requests should be ad-
dressed. NREg sequence as the probe. As shown in Fig. 2A, in
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the presence of the HeLa nuclear extract, a shifted band
(denoted by an arrowhead) was detected (lane 2), indicat-
ing binding by a protein factor to the NREg sequence.
This shifted band could be entirely supershifted by a
rabbit antibody directed against RFX1 (lane 3), but not
by a control rabbit antibody (lane 4). A similar result was
obtained when Huh7 nuclear extract was used for the
experiment (data not shown). Therefore, RFX1 appears
to bind NREg. To confirm this result, a different approach
employing both EMSA and Western blot assay was used
to investigate whether RFX1 could bind to the NREg site.
HeLa nuclear extract incubated with or without unlabeled
NREg oligonucleotide was subjected to electrophoresis
in a low-ionic-strength gel, transferred to nitrocellulose
membrane, and probed with anti-RFX1 antibody. As
shown in Fig. 2B, an intense signal was detected only
when the NREg oligonucleotide was used in the binding
reaction (lane 2, denoted by an arrow). The lack of the
Western blot signal in the absence of the NREg oligonu-
cleotide was likely due to the inability of the RFX1 protein
to enter the nondenaturing, low-ionic-strength gel during
electrophoresis (11). This result supports the result of
Fig. 2A and indicates that RFX1 indeed binds to the NREg
sequence.
FIG. 2. Analysis of binding by RFX1 to the NREg motif. (A) SupershiftTo examine the effect of RFX1 on NREg activity, we
assay. EMSA was performed as previously using 5 mg HeLa nuclearnext performed transfection experiments in Huh7 hepa-
extract and a 28mer double-stranded oligonucleotide containing thetoma cells. As a control, a plasmid containing mutations
NREg-binding site (4). Lane 1, probe alone; lane 2, with nuclear extract;
in the NREg site was also used. To ensure that the muta- lane 3, nuclear extract plus rabbit anti-RFX1 antibody (gift of M. Peterlin
tions introduced into the NREg site would prevent bind- and N. Jabrine-Ferrat); lane 4, nuclear extract plus a control antibody.
The NREg-specific band and the supershifted band are denoted by aning by the NREg factor, we first performed an EMSA
arrowhead and an arrow, respectively. The position of free probe isexperiment. As shown in Fig. 3A, while the wild-type
also marked. (B) EMSA–Western blot assay. The procedures of thisoligonucleotide could be bound by the NREg factor (lane
assay have been described in detail in (11). Briefly, EMSA was per-
2), the mutant could no longer be bound by the protein formed as in (A) except that the NREg oligonucleotide was not labeled,
factor (lane 4). The full-length NRE, with or without the the amount of the oligonucleotide used was increased 10-fold, and the
thickness of the gel was increased from 0.8 to 1.5 mm. Followingmutations in the NREg site, and its downstream core
electrophoresis, the gel was transferred to nitrocellulose membrane inpromoter were next linked to the chloramphenicol acetyl
0.4% sodium dodecyl sulfate, 48 mM Tris base, 39 mM glycine, and 20%transferase (CAT) reporter and cotransfected with an
methanol. The membrane was then hybridized with anti-RFX1 primary
RFX1 expression plasmid into Huh7 cells. As shown in antibody and horseradish peroxidase-conjugated goat anti-rabbit sec-
ondary antibody (Sigma Biochemicals). The signal was developed using
a Chemiluminescence kit (Dupont-NEN). Lane 1, without NREg DNA;
lane 2 with NREg DNA. The arrow marks the location of the DNA–
RFX1 complex.
Fig. 3B, cotransfection with RFX1 led to an approximately
fourfold increase of the core promoter activity of pUCAT1
which contained the wild-type NREg sequence. In con-
trast, pUCAT10, which contained the mutated NREg se-
quence, was no longer responsive to transactivation by
RFX1. These results indicate that the transactivation of
the core promoter by RFX1 is mediated by the NREg site
and that the NREg protein-binding activity is essential for
FIG. 1. HBV core promoter and sequence homology between NREg this transactivation. Similar transactivation results were
and RFX1. a, b, and g represent the three subregions of the NRE. The obtained with HeLa cells in our preliminary cotransfec-
solid box represents the HNF4 binding site. Cp, core promoter; ENII,
tion experiments.the ENII enhancer. Dots mark the identical nucleotide residues be-
The finding that RFX1 stimulated core promoter activitytween the NREg motif and the consensus RFX1-binding site (7). The
arrow marks the initiation sites of the C gene transcripts. was surprising, because if RFX1 is indeed the NREg
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factor, it is anticipated to suppress, rather than to stimu-
late, core promoter activity. Recently, it has been demon-
strated that RFX1 can form a heterodimer with the myc
intron-binding protein (MIBP1) and that this heterodimer
possesses a gene-suppressive activity (7). For this rea-
son, we have investigated whether the NREg factor is a
heterodimer of RFX1 and MIBP1 by performing a su-
pershift assay using an antibody directed against MIBP1.
As shown in Fig. 4, the anti-MIBP1 antibody, which does
not cross-react with RFX1 (7), supershifted all of the
NREg-binding activity (lane 2) while a control serum did
not (lane 3). Since the anti-RFX1 antibody also entirely
supershifted the NREg-binding activity (Fig. 2A), RFX1
and MIBP1 must bind simultaneously, most likely as a
heterodimer, to the NREg sequence. The ubiquitous na-
ture of RFX1 and MIBP1 is consistent with the observa-
tion that the NREg factor is present in both Huh7 and
HeLa cells. In contrast to RFX1, the role of MIBP1 in the
regulation of the NREg activity cannot be assessed at
present as the gene encoding this protein factor has not
yet been isolated.
While our EMSA results indicate that RFX1 and MIBP1
can bind simultaneously to the NREg site, our previous
cross-linking experiment indicated that only a 130-kDa
protein bound to the NREg DNA (4). Since RFX1 and
MIBP1 are approximately 130 and 160 kDa in size (7),
FIG. 3. (A) Analysis of NREg factor binding to the mutated NREg
sequence. The mutated double-stranded NREg oligonucleotide used
in EMSA was
5* TCGAGCACTGATATCCTGCAGCACCGTG 3*
3* CGTGACTATAGGACGTCGTGGCACAGCT 5*.
In this mutated sequence, 12 basepairs (underlined) of the NREg motif
were replaced with other nucleotides. Lanes 1 and 2, NREg wild-type
(WT) probe employed; lanes 3 and 4, NREg mutant (MT) probe; lanes
1 and 3, without (0) nuclear extract (NE); lanes 2 and 4, with (/) nuclear
extract. No shifted signal (denoted by an arrow) was detected when
the mutated NREg probe was used for EMSA. The position of free
probe (P) is also indicated. (B) Transactivation of the core promoter by
RFX1. 60-mm plates of Huh7 cells were transfected using the CaPO4
precipitation method (16) with 4 mg wild-type NREg motif-containing
pUCAT1 (WT) or the mutated NREg motif-containing pUCAT10 (MT),
and 5 mg of either pRc/CMV (Invitrogen) control or the RFX1 expression
plasmid, pCMV-RFX1. Two days posttransfection, cell lysates were ana-
lyzed for CAT activity as previously (4). The results shown represent
the mean and the standard deviation of three different transfection
experiments. Fold CAT activity is relative to the pRc/CMV control with-
out pCMV-RFX1 cotransfection. The construction of pUCAT1 has been
described (4). pUCAT10 is identical to pUCAT1 except that it contains FIG. 4. Supershift analysis of the NREg factor with anti-MIBP1 anti-
the nucleotide mutations shown above. pCMV-RFX1 was constructed body. The supershift experiment was performed as in Fig. 2A except
by inserting the EcoRI fragment of pUC19-RFX1 (gift of M. Peterlin and an anti-MIBP1 antibody (gift of M. Zajac-Kaye) was used. Lane 1, probe
N. Jabrine-Ferrat) containing the RFX1 coding sequence into the EcoRI alone; lane 2, with HeLa nuclear extract; lane 3, with nuclear extract
site of a CMV vector (17). In this plasmid, the expression of RFX1 was and anti-MIBP1 antibody; lane 4, with nuclear extract and preimmune
under the control of the cytomegalovirus immediate early promoter. In rabbit serum. The arrow indicates the supershifted band while the
the absence of RFX1, the activity of MT is two- to threefold higher than arrowhead indicates the NREg-specific bandshift. The position of free
that of WT. This result is consistent with our previous findings (4). probe is also indicated.
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ments, RFX1 was found to stimulate gene expression
through the EP site (13). Since the HBV ENI enhancer
requires the EP site and its juxtaposed HNF3- and HNF4-
binding sites for basal activity (3, 4, 14–16), it has been
postulated that these cis-acting elements play an im-
portant role converting the silencer activity of the EP site
into an enhancer (13). In the case of NREg, it is possible
that flanking cis-acting elements also play important
roles in modulating RFX1 activity to regulate core gene
expression. Alternatively, it is also possible that RFX1
functions as a positive regulator of the core promoter,
and, in the presence of MIBP1, which can bind to RFX1
(7), RFX1 is converted into a negative regulator to sup-
press the core promoter through its NREg-binding site.
This dual activity of RFX1 may be important for differential
regulation of HBV gene expression during the viral life
cycle.
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